Amylin 3 receptor (AMY3) (AMY3)

The Amylin 3 receptor (AMY3) is a heterodimeric G protein-coupled receptor (GPCR) formed by the association of the calcitonin receptor (CTR) and the receptor activity-modifying protein 3 (RAMP3) (IUPHAR/BPS Guide to PHARMACOLOGY). It serves as a primary mediator for the physiological effects of amylin, a peptide hormone co-secreted with insulin by pancreatic beta cells (Hay et al., 2015, Biochemical Society Transactions). AMY3 is predominantly expressed in the central nervous system, particularly in the area postrema of the hindbrain, where it regulates energy balance by promoting satiety and slowing gastric emptying (Lutz, 2010, American Journal of Physiology). In the context of metabolic diseases, AMY3 is a significant therapeutic target for managing body weight and glycemic levels (Boyle et al., 2018, Free Radical Biology and Medicine). Amylin analogues, such as the FDA-approved pramlintide and the investigational long-acting agonist cagrilintide, exert their effects by activating this receptor complex (Enebo et al., 2021, The Lancet). Beyond metabolic control, AMY3 signaling is involved in the inhibition of glucagon secretion and may play roles in bone remodeling (Young, 2005, Advances in Pharmacology). Overall, AMY3 represents a validated target for the dual treatment of obesity and type 2 diabetes due to its integrated role in appetite and glucose regulation.

Other names

CTR/RAMP3 complexCalcitonin receptor/RAMP3 heterodimerAmylin receptor 3

Agonism of the AMY3 receptor complex leads to activation of intracellular signaling pathways, primarily Gs-mediated cAMP production, resulting in reduced food intake and delayed gastric emptying.